Use of chemotherapy, chemoradiation for cervical cancer increased between 1997 and 2001

September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p16
The article reports on a U.S. study which found a sharp increase in the percentage of women who received chemotherapy or concurrent chemoradiation for cervical cancer between 1997 and 2001. The increase is attributed by researchers to the publication of results from five studies in 1999 that demonstrated a correlation between chemoradiation and improved overall survival (OS). The study results also indicate an inverse relationship between age and the use of chemotherapy or chemoradiation.


Related Articles

  • Comparison of Axxent-Xoft, 192lr and 60Co high-dose-rate brachytherapy sources for image-guided brachytherapy treatment planning for cervical cancer. MOBIT, P. N.; PACKIANATHAN, S.; HE, R.; YANG, C. C. // British Journal of Radiology;Aug2015, Vol. 88 Issue 1052, p1 

    Objective: To evaluate the dosimetric differences and similarities between treatment plans generated with Axxent-Xoft electronic brachytherapy source (Xoft-EBS), 192lr and 60Co for tandem and ovoids (T&O) applicators. Methods: In this retrospective study, we replanned 10 patients previously...

  • Experience in stage IB2 cervical cancer and review of treatment. Turan, Taner; Yıldırım, Burcu Aykan; Tulunay, Gökhan; Boran, Nurettin; Yıldız, Ferah; Köse, Mehmet Faruk // Journal of the Turkish-German Gynecological Association;Mar2010, Vol. 11 Issue 1, p27 

    Objective: The aim of the study is to evaluate and compare the efficacy of neoadjuvant chemotherapy (NACT), radical hysterectomy (RH) and radiotherapy (RT) in the treatment of stage IB2 cervical cancer. Material and Methods: Medical records of 86 patients with stage IB2 cervical cancer between...

  • Impact of Distant Metastasis in Patients With Cervical Lymph Node Metastases From Cancer of an Unknown Primary Site. Rödel, Ralph M. W.; Matthias, Christoph; Blomeyer, Barbara D.; Wolff, Hendrik A.; Jung, Klaus; Christiansen, Hans // Annals of Otology, Rhinology & Laryngology;Sep2009 Part 1 of 2, Vol. 118 Issue 9, p662 

    Objectives: Treatment methods for patients with cervical cancer of an unknown primary site (CUP) are still under discussion. The purpose of this retrospective study was to analyze the oncological follow-up of 58 patients treated for cervical CUP. Methods: From 1986 to 2006,58 patients with...

  • Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin. D'Agostino, Giuseppe; Distefano, Mariagrazia; Greggi, Stefano; Salerno, MariaGiovanna; Ferrandina, Gabriella; Poerio, Antonella; Mancuso, Salvatore; Scambia, Giovanni // Cancer Chemotherapy & Pharmacology;Mar2002, Vol. 49 Issue 3, p256 

    Purpose: The present study was conducted to explore whether neoadjuvant chemotherapy with a combination of epirubicin, paclitaxel and cisplatin could improve the operability and pathological response rate in locally advanced cervical cancer patients. Methods: Between April 1996 and July 2000, 42...

  • Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. Nagai, Tomonori; Okubo, Takashi; Sakaguchi, Riko; Seki, Hiroyuki; Takeda, Satoru // International Journal of Clinical Oncology;Dec2008, Vol. 13 Issue 6, p541 

    Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis. Saitama Medical Center has been offering neoadjuvant intraarterial chemotherapy (NAC) to cervical cancer patients as a means of...

  • Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer. Lopez-Graniel, Carlos; Dolores, Rigoberto; Cetina, Lucely; Gonzalez, Aaron; Cantu, David; Chanona, Jose; Uribe, Jesus; Candelaria, Myrna; Brom, Rocio; de la Garza, Jaime; Duenas-Gonzalez, Alfonso // BMC Cancer;2005, Vol. 5, p118 

    Background: Most cervical cancer patients with pelvic recurrent or persistent disease are not candidates for exenteration, therefore, they only receive palliative chemotherapy. Here we report the results of a novel treatment modality for these patients pre-exenterative chemotherapy- under the...

  • Fertility Preservation in Cancer Patients:Providing Hope at a Challenging Time. Glass, Karen B. // University of Toronto Medical Journal;May2012, Vol. 89 Issue 3, p113 

    The article presents the author's views on the preservation of fertility in cancer patients. According to the author, thousands of adolescents and young adults suffer from cancer every year; and the treatment for their cancer can make them infertile. The author says that female patients...

  • Cisplatin + topotecan does not reduce QOL in cervical cancer.  // PharmacoEconomics & Outcomes News;7/2/2005, Issue 481, p12 

    Provides information on research regarding combination therapy with cisplatin plus topotecan in patients with advanced or recurrent cervical cancer. Methods used to asses the quality of life (QOL) of patients with the disease; Factor which indicated an improvement in pain symptoms; Effect of...

  • Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. F Bellati; M Pernice; N Manci; I Palaia; F Tomao; C Marchetti; MA Zullo; L Muzii; R Angioli; P. Benedeth Panici // Annals of Oncology;Apr2007, Vol. 18 Issue 4, p722 

    Background: The objectives of the present study were to evaluate hemoglobin levels and consequent clinical behaviors related to anemia developed in patients affected by locally advanced cervical cancer treated with neo-adjuvant chemotherapy in the last decade and to evaluate the impact that the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics